Quick Answer
Black Diamond Therapeutics, Inc. reported Net Income Loss of $22.37 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +132.1% in Net Income Loss from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$1.59 million | Q2 2018: -$1.91 million | Q3 2018: -$2.36 million | Q4 2018: -$3.07 million | Q1 2019: -$3.83 million | Q2 2019: -$12.29 million | Q3 2019: -$9.27 million | Q4 2019: -$9.88 million | Q1 2020: -$12.15 million | Q2 2020: -$14.57 million | Q3 2020: -$17.91 million | Q4 2020: -$22.63 million | Q1 2021: -$30.30 million | Q2 2021: -$34.35 million | Q3 2021: -$35.08 million | Q1 2022: -$25.51 million | Q2 2022: -$22.93 million | Q3 2022: -$21.65 million | Q1 2023: -$20.88 million | Q2 2023: -$19.15 million | Q3 2023: -$23.01 million | Q1 2024: -$18.23 million | Q2 2024: -$19.91 million | Q3 2024: -$15.56 million | Q1 2025: $56.54 million | Q2 2025: -$10.56 million | Q3 2025: -$8.50 million.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Net Income Loss has grown by 350.4%.
- Historical annual values: Fiscal year 2025: $22.37 million | Fiscal year 2024: -$69.68 million | Fiscal year 2023: -$82.44 million | Fiscal year 2022: -$91.17 million | Fiscal year 2021: -$125.60 million | Fiscal year 2020: -$67.25 million | Fiscal year 2019: -$35.26 million | Fiscal year 2018: -$8.93 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: